Navigation Links
Everist Genomics Announces Acquisition of Angiologix, Inc.
Date:10/31/2011

ANN ARBOR, Mich., Oct. 31, 2011 /PRNewswire/ -- Everist Genomics, a rapidly growing personalized medicine company developing and commercializing innovative diagnostics and prognostics, announced today that it has successfully completed acquisition of 100% of the shares of Angiologix, Inc., the developer of the AngioDefender™ diagnostic device for assessing endothelial function.  Endothelial cell dysfunction is a key biomarker of early-stage atherosclerosis and CVD; it is also the earliest detectable sign of atherosclerosis. (1)

(Photo: http://photos.prnewswire.com/prnh/20111031/NY96250 )

(Logo: http://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

AngioDefender is a highly accurate and low-cost tool designed to allow physicians to assess endothelial function -- a key indicator of blood vessel health.  Clinical syndromes such as stable and unstable angina, acute myocardial infarction, claudication, and stroke relate, in part, to a loss of endothelial control of vascular tone, thrombosis, and the composition of the vascular wall. (2) Such a tool could aid in the diagnosis of early stage atherosclerosis and cardiovascular disease (CVD) in asymptomatic patients.  Clinical studies (3) show that pharmacological and life style interventions are effective in treating endothelial dysfunction; these interventions are also efficacious in treating CVD:Intervention/TreatmentEffect on Endothelial FunctionEffect on CVD EventsLipid-lowering therapyBeneficial

BeneficialSmoking cessationBeneficial

BeneficialExerciseBeneficial

BeneficialACE Inhibitors

Beneficial

BeneficialAngiotensin receptor blockers

Beneficial

BeneficialN-3 fatty acids

Beneficial

BeneficialGlycemic control in diabetes mellitus

Beneficial

BeneficialThe endothelium, a thin layer of cells that line the walls of every blood vessel, is
'/>"/>

SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
2. Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
3. Genetics Squared Changes Name To Everist Genomics
4. Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President
5. Cancer Game Changers: Genomics, Smarter Medicine, Care Coordination Comprise Medcos Advanced Oncology Solutions™
6. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
7. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
8. Rosetta Genomics Announces Issuance of Additional U.S. Patent
9. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
10. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
11. NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 2American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 3American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 4American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 5American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 6American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 7Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 2Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 3Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 4
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Social networking ... new study. For people who are obese, sites ... convenient source of support from doctors as well as ... media over other methods is that it offers the ... for day-to-day use when compared to traditional approaches," the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Sept. 17, 2014 (HealthDay News) -- Positive messages about ... people kick the habit, a new study suggests. ... better to "loss-framed" messages about the harmful effects of ... whenever they want benefit more from "gain-framed," or positive, ... The researchers concluded that using a mix of both ...
(Date:9/17/2014)... 2014 Many countries choose to kill ... immunizations. The total number of poultry exceeds 10 billion ... will result in huge losses. Therefore, it is quite ... , Avian influenza vaccines have been used for more ... China began to use H5N1 avian influenza vaccines voluntarily ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
Breaking Medicine News(10 mins):Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... Campath, CAMBRIDGE, Mass. and WAYNE, N.J., Sept. ... Bayer HealthCare Pharmaceuticals Inc.,(NYSE: BAY ) today ... has approved a supplemental biologics license application (sBLA) ... for the treatment of B-cell chronic lymphocytic leukemia ...
... LLC, today announced the,U.S. Food and Drug Administration ... use in intervertebral fusion procedures.,Included are versions to ... without the need for supplemental fixation. Fusion ... performed by,neurosurgeons and orthopedic spine surgeons. The InterPlate ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... chronic,lymphocytic leukemia (CLL). CLL is a slowly progressing ... new cases diagnosed every year in,the United States, ...
... new implant for marketing, NEW YORK, Sept. 21 ... products, technology and education for the,small bone and joint ... Spacer has been cleared by the FDA for marketing ... of surgically implanted, degradable,spacers to four applications with two ...
... you eat the right grains for breakfast, such as ... sugar is facilitated after breakfast, lunch, and dinner. It ... this effect all day. This is due to a ... of indigestible carbohydrates that occur in certain grain products. ...
... Aviv Universitys Sackler School of Medicine is, quite simply, a ... of a small number of surgeons in the world who ... has developed a novel laser device that promises to revolutionize ... now, is expected to give most practicing eye surgeons the ...
Cached Medicine News:Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:Glaucoma surgery in the blink of an eye 2
Inquire...
... The Trinity Biotech Captia™ Mumps IgG ... the detection and quantitative determination of IgG ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
... AUTOMATION, INC. (DAI) Mumps IgG ... intended for the detection and ... to Mumps virus in human ... be used for the determination ...
... Corporation announced the launch of the ... first bi-directional cooled-tip catheter available in the ... offers physicians the benefits of cooled ablation ... the Boston Scientific Blazer(R) catheter platform. ,Cooled ...
Medicine Products: